2′,3′-Di-O-acetyl-5′-deoxy-5-fluorocytidine CAS 161599-46-8 Purity ≥99.0% Capecitabine Intermediate Factory

Short Description:

Name: 2′,3′-Di-O-acetyl-5′-deoxy-5-fluorocytidine

CAS: 161599-46-8

Appearance: Whitish or Yellowish Crystalline Powder

Assay: ≥99.0% Purity: ≥99.0% (HPLC)

Intermediate of Capecitabine (CAS: 154361-50-9)

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Commercial Supply Capecitabine Related Intermediates:
5-Fluorocytosine CAS: 2022-85-7
2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine CAS: 161599-46-8
1,2,3-Tri-O-acetyl-5-deoxy-β-D-ribofuranose CAS: 62211-93-2
Capecitabine CAS: 154361-50-9

Chemical Properties:

Name	2',3'-Di-O-acetyl-5'-deoxy-5-fluorocytidine
CAS Number	161599-46-8
CAT Number	RF-PI176
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C13H16FN3O6
Molecular Weight	329.28
Condition to Avoid	Heat Sensitive
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Whitish or Yellowish Crystalline Powder
Single Impurity	≤0.50%
Total Impurities	≤1.0%
Melting Point	178.0~193.0℃
Loss on Drying	≤0.50%
Residue on Ignition	≤0.10%
Moisture (K.F)	≤1.0%
Assay	≥99.0%
Purity / Analysis Method	≥99.0% (HPLC)
Test Standard	Enterprise Standard
Usage	Intermediate of Capecitabine (CAS: 154361-50-9)

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

FAQ:

Application:

Capecitabine (CAS: 154361-50-9) is a new form of oral fluorinated pyrimidine drug. Capecitabine was developed by Roche Pharmaceuticals, and its commercial name is Xeloda. Capecitabine can change in vivo into 5- FU, an anti-metabolizim fluorine pyrimidine deoxynucleoside carbamate drug that targets cancer cells to inhibit cell division and disrupt RNA and protein synthesis. Its effects are significantly tied to the level of TP enzyme expression in neoplastic tissue and to DPD enzyme in vivo expression. It is suitable as further treatment for advanced primary or metastatic breast cancer patients who have not responded to paclitaxel or anthracycline antibiotics. As an anticancer drug, it is mostly used to treat advanced primary or metastatic breast cancer, as well as in treatment for non-small cell lung cancer, pancreatic cancer, bladder cancer, rectal cancer, colon cancer, gastric cancer, and other solid tumors.